[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650942":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":59,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":25,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":83,"overallStatus":86,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Combined dexmedetomidine-esketamine group","EXPERIMENTAL","During anesthesia, a loading dose (0.8 ml\u002Fkg\u002Fh) of dexmedetomidine-esketamine (DEX-ESK) combination (DEX 1 ug\u002Fml; ESK 0.5 mg\u002Fml) will be infused after anesthesia induction for 30 min (DEX 0.4 ug\u002Fkg; ESK 0.2 mg\u002Fkg), followed by a continuous infusion at 0.1 ml\u002Fkg\u002Fh (DEX 0.1 ug\u002Fkg\u002Fh; ESK 0.05 mg\u002Fkg\u002Fh) until 1 hour before the expected end of surgery.\n\nAfter surgery, patient-controlled intravenous analgesia will be established with dexmedetomidine (DEX 1.5 ug\u002Fml), esketamine (ESK 0.25 mg\u002Fml), and sufentanil (1.0 ug\u002Fml), programmed to deliver 2-ml boluses (DEX 3.0 ug, ESK 0.5 mg, and sufentanil 2.0 ug) with an 8-minute lockout interval and a 1-ml\u002Fh (DEX 1.5 ug\u002Fh, ESK 0.25 mg\u002Fh, and sufentanil 1.0 ug\u002Fh) background infusion, and used for up to 48 hours.",[13],"Drug: Combined dexmedetomidine-esketamine administration",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","During anesthesia, a loading dose (0.8 ml\u002Fkg\u002Fh) of normal saline will be infused after anesthesia induction for 30 min, followed by a continuous infusion at 0.1 ml\u002Fkg\u002Fh until 1 hour before the expected end of surgery.\n\nAfter surgery, patient-controlled intravenous analgesia will be established with sufentanil (1.0 ug\u002Fml), programmed to deliver 2-ml boluses (sufentanil 2.0 ug) with an 8-minute lockout interval and a 1-ml\u002Fh (sufentanil 1.0 ug\u002Fh ) background infusion, and used for up to 48 hours.",[19],"Drug: Placebo administration",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Combined dexmedetomidine-esketamine administration",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo administration","During anesthesia, a loading dose (0.8 ml\u002Fkg\u002Fh) of normal saline will be infused after anesthesia induction for 30 min, followed by a continuous infusion at 0.1 ml\u002Fkg\u002Fh until 1 hour before the expected end of surgery.\n\nAfter surgery, patient-controlled intravenous analgesia will be established with sufentanil (1.0 ug\u002Fml), programmed to deliver 2-ml boluses (sufentanil 2.0 ug) with an 8-minute lockout interval and a 1-ml\u002Fh (sufentanil 1.0 ug\u002Fh) background infusion, and used for up to 48 hours.",[15],[31],{"name":32,"affiliation":5,"role":33},"Dong-Xin Wang","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Dong-Xin Wang, MD, PhD","CONTACT","8610 83572784","wangdongxin@hotmail.com",{"name":41,"role":37,"phone":42,"phoneExt":25,"email":43},"Chun-Qing Li, MD","8610 83575138","lichuntsing@163.com",[45],{"facility":5,"status":25,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Beijing","Beijing Municipality","100034","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58],{"name":32,"role":37,"phone":38,"phoneExt":25,"email":39},{"type":33,"investigatorFullName":32,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Professor and Chairman, Department of Anesthesiology","100650942","dexmedetomidine-esketamine-combination-on-depression-and-anxiety-after-laparoscopic-ureteral-reconstruction-100650942",false,"NCT07753772","Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction","Perioperative Use of Dexmedetomidine-esketamine Combination on Depression and Anxiety in Patients Undergoing Laparoscopic Ureteral Reconstruction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged ≥ 18 years;\n2. Diagnosed with ureteral stricture and scheduled for elective laparoscopic ureteral reconstruction under general anesthesia;\n3. Requiring patient-controlled intravenous analgesia after surgery.\n\nExclusion Criteria:\n\n1. Preoperative inability to communicate due to coma, delirium, severe dementia, or language barrier;\n2. History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n3. Presence of preexisting left ventricular ejection fraction (LVEF) \\\u003C 30%, sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), or atrioventricular block above grade II without pacemaker implanted;\n4. Uncontrolled hyperthyroidism or history of pheochromocytoma;\n5. Severe hepatic insufficiency (Child-Pugh Class C), severe renal insufficiency (required preoperative dialysis), or American Society of Anesthesiologists (ASA) physical status classification ≥ IV;\n6. Allergy to dexmedetomidine and\u002For esketamine;\n7. Other conditions deemed unsuitable for study participation by the investigators.","ALL","18 Years",{"count":71,"type":72},658,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","Anxiety and depressive symptoms are prevalent in patients undergoing surgical repair for ureteral stricture, driven by chronic pain, renal function concerns, and surgical uncertainty. Dexmedetomidine has anxiolytic and antidepressant effects but may increase bradycardia and hypotension; esketamine provides rapid antidepressant efficacy but may cause psychiatric side effects. Preliminary studies showed that combined use of low-dose dexmedetomidine and esketamine reduced the prevalence of postoperative depressive symptoms without increasing adverse events. This study is designed to test the hypothesis that perioperative use of low-dose dexmedetomidine-esketamine combination may relieve postoperative depressive symptoms and anxiety in patients undergoing laparoscopic ureteral reconstruction.",[78,79,80,81,82],"Ureteral Stricture","Dexmedetomidine","Esketamine","Depressive Symptoms","Anxiety",[84,79,80,85,82],"Laparoscopic ureteral reconstruction","Depressive symptoms","NOT_YET_RECRUITING","2026-08-12",{"date":89,"type":90},"2026-08-14","ACTUAL",{"date":92,"type":72},"2026-08",{"date":94,"type":72},"2029-08",{"name":5,"class":6},1]